Office-based vergence/accommodative therapy with home reinforcement (OBVAT) is the most effective method of treating symptomatic convergence insufficiency when compared with any other home- or office-based placebo or therapy, according to study results published in the October issue of the Archives of Ophthalmology.
A series of debates on the most relevant, and most controversial, topics in ophthalmology, in which today's most eminent ophthalmologists argue for the validity of their differing opinions and practices.
HOYA Surgical Optics has been distributing IOLs to ophthalmic surgeons in Europe since 2003. The name HOYA, however, represents more than just IOLs; the firm has a long tradition in high tech optics…
Laser in situ keratomileusis buttonhole: Classification and management algorithm
Clinical findings following Ahmed Glaucoma Valve implantation in pediatric glaucoma
The Phase I three-year feasibility study of the Argus II Retinal Implant for Retinitis Pigmentosa (RP) will be expanded to enrol more patients in Europe, according to an announcement from Second Sight Medical Products, the implant's manufacturer.
An ophthalmology network, aiming to prevent loss of vision across the country, has been established in Wales.
The growing understanding that glaucoma is a neurodegenerative rather than ocular disease is to be the principal topic of discussion of the annual Glaucoma Research Foundation (GRF) benefit, to be held January 28 2009 in San Francisco, California, US.
The methods used to manage glaucoma vary widely across the United Kingdom, according to study results published in the November issue of Eye.
Risk Factors for Retinal Hemorrhage after Photodynamic Therapy in Age-Related Macular Degeneration
STAAR Surgical has created the Collamer Accommodating Study Team (CAST), a group of seven ophthalmologists who will investigate the accommodative properties of STAAR's Collamer intraocular lens (IOL).
The Phase IIb trial assessing the safety and efficacy of microplasmin in patients, showed complete resolution of vitreomacular traction or macular hole without need for vitrectomy surgery, according to a statement from the trial sponsor, ThromboGenics NV.
Second-line therapy with dorzolamide/timolol or latanoprost/timolol fixed combination versus adding dorzolamide/timolol fixed combination to latanoprost monotherapy
A Comparison of the Glaucoma Probability Score to Earlier Heidelberg Retina Tomograph Data Analysis Tools in Classifying Normal and Glaucoma Patients
Topcon Medical Systems has introduced new OCT mapping software and enhanced its image management system.
Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study
23-gauge versus 20-gauge system for pars plana vitrectomy: a prospective randomised clinical trial
A cleaning solution for silicone intraocular lenses: "sticky silicone oil"
Contact anaesthesia is just as safe and effective as peribulbar application for combined cataract and glaucoma surgery, according to study results published online ahead of print by Ophthalmologica.
Performing selective laser trabeculoplasty (SLT) in patients with pseudoexfoliative glaucoma (PEXG) may in fact cause a rise in intraocular pressure (IOP), according to results published in the October issue of BMC Ophthalmology.
Ellex's 2RT, a Retina Regeneration Therapy, is safe and effective in the treatment of macular oedema (ME) secondary to diabetic retinopathy (DR), according to study results presented at this year's American Academy of Ophthalmology meeting.
The Lamellar Corneal Surgery Module (LCS Module), with a hand-piece that can cut depths of 250?450 µm, has been released by Ziemer Group.
Four new ophthalmic lasers and delivery devices have been unveiled by Lumenis at the meeting of the American Academy of Ophthalmology.
Following limited reports of adverse events encountered by US physicians using a particular batch of Healon D viscoelastic, AMO has recalled the remaining products in the batch.
The level of reimbursement of Optonol's Ex-PRESS Mini Glaucoma Shunt has been increased by the US Centers for Medicare and Medicaid (CMS), according to an announcement made by Optonol at the Glaucoma Subspecialty Day of this year's meeting of the American Academy of Ophthalmology.
A Phase I trial of POT-4, a complement inhibitor in development for the treatment of age-related macular degeneration (AMD), have demonstrated that the agent is safe and well tolerated. The results were presented by Potentia Pharmaceuticals during the Retina Subspecialty Day at the meeting of the American Academy of Ophthalmology.
CataractSurgery.com, an online resource for patient education, has been launched by Alcon, Inc.
The Latanoprost punctal plug drug delivery system (L-PPDS) has performed well in its Phase II CORE trial, according to study data released by the manufacturer, QLT Plug Delivery Inc.
The introduction of anti-glaucoma medications has reduced the need for filtration surgery, according to study results published online ahead of print by Eye.
